Patent ID: 6211209
Filing Date: 2001-04-03
Classification: A61K

Abstract:
A method of inhibiting connective tissue degradation, the method comprising administering to a patient having a condition in which connective tissue is degraded a therapeutically effective amount of a compound having the formula ##STR47##where R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently hydrogen, hydroxy, halo, amino, nitro, C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.1 -C.sub.6 alkoxy, CF.sub.3, CN, S(O).sub.n --[C.sub.1 -C.sub.6 alkyl], ##STR48##R.sub.6 and R.sub.7 are independently hydrogen, C.sub.1 -C.sub.6 alkyl or acyl;n is 0 to 2;R.sub.8 is hydrogen or C.sub.1 -C.sub.6 alkyl; ##STR49##W is S or O;Z is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, or NR.sub.9 R.sub.10 ;R.sub.9 and R.sub.10 are independently hydrogen or C.sub.1 -C.sub.6 alkyl; andR.sub.5 is ##STR50##where Y is hydroxy, thiol, amino, or NHCN;X is sulfur or oxygen; and Q is sulfur, oxygen, NH, or NCN, and the pharmaceutically acceptable salts and prodrugs thereof.